An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Puma Biotechnology (NASDAQ: PBYI) announced the titles of abstracts for neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. Key studies include the SUMMIT trial on neratinib with fulvestrant and trastuzumab for HR+, HER2-negative, HER2-mutant metastatic breast cancer, and targeting HER2 mutation-positive advanced biliary tract cancers. Full abstracts will be available online on May 26.
Positive
Presentation of new clinical data on neratinib could enhance market interest and investor confidence.
Potential to address unmet medical needs in metastatic breast and biliary tract cancers.
Negative
None.
LOS ANGELES--(BUSINESS WIRE)--
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of titles of abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held at McCormick Place in Chicago and online from June 3-7. Posters will be available on Puma’s website following presentation.
Abstract 1028: Neratinib + fulvestrant + trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial
Presenter: Komal L. Jhaveri, FACP, MD | Memorial Sloan Kettering Cancer Center
Abstract 4079: Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
Presenter: James J. Harding, MD | Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College
About Puma Biotechnology:
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission in September 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
What are the key abstracts presented by Puma Biotechnology related to neratinib at ASCO 2022?
Puma Biotechnology presents two key abstracts at ASCO 2022, focusing on neratinib combined with fulvestrant and trastuzumab for HR+, HER2-negative, HER2-mutant metastatic breast cancer, and targeting HER2 mutation-positive advanced biliary tract cancers.
When is the ASCO Annual Meeting where Puma Biotechnology will present?
The ASCO Annual Meeting will take place from June 3-7, 2022, in Chicago and online.
Where can I access the full abstracts of Puma's presentations at ASCO 2022?
Full abstracts will be available online on May 26, 2022, on the ASCO conference website.
What is the significance of neratinib in cancer treatment according to Puma Biotechnology's research?
Neratinib is significant for its potential to treat HR+, HER2-negative, HER2-mutant metastatic breast cancer and HER2 mutation-positive advanced biliary tract cancers, addressing critical needs in oncology.
